Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $1.7 million.

  • Seres Therapeutics' Accounts Payables fell 7968.26% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 7968.26%. This contributed to the annual value of $4.1 million for FY2024, which is 1202.97% up from last year.
  • Seres Therapeutics' Accounts Payables amounted to $1.7 million in Q3 2025, which was down 7968.26% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Accounts Payables registered a high of $17.4 million during Q4 2022, and its lowest value of $1.7 million during Q3 2025.
  • Its 5-year average for Accounts Payables is $7.8 million, with a median of $6.8 million in 2022.
  • In the last 5 years, Seres Therapeutics' Accounts Payables surged by 24183.67% in 2021 and then crashed by 7968.26% in 2025.
  • Over the past 5 years, Seres Therapeutics' Accounts Payables (Quarter) stood at $13.7 million in 2021, then grew by 26.97% to $17.4 million in 2022, then tumbled by 79.12% to $3.6 million in 2023, then grew by 12.03% to $4.1 million in 2024, then tumbled by 58.89% to $1.7 million in 2025.
  • Its Accounts Payables stands at $1.7 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.2 million for Q1 2025.